SCHEMBL3548729

SCHEMBL3548729

COc1cc2c(cc1OC)C(Cc1ccc(-c3ccc(C)cc3)cc1)(OC(=O)C(=O)OC1(Cc3ccc(-c4ccc(C)cc4)cc3)NCCc3cc(OC)c(OC)cc31)NCC2

nearest known ligand 0.39

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 8/20 0.36
ABCC1 P33527 2/20 0.36
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
ALDH1A1 P00352 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
EPHX2 P34913 1/20 0.34
BCHE P06276 1/20 0.34
ABCG2 Q9UNQ0 1/20 0.34
ACHE P22303 1/20 0.34
BDKRB1 P46663 1/20 0.33
PARP1 P09874 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5090771 0.92 KMT2A (0.40) ABCB1ABCC1LMNAALDH1A1PARP1
SCHEMBL3544102 0.91 ABCB1 (0.42) ABCB1ABCC1LMNANPSR1
SCHEMBL3546929 0.87 HCRTR1 (0.40) ABCB1ALDH1A1BCHEABCG2ACHE
SCHEMBL3548501 0.84 CFD (0.37) ABCB1PARP1
SCHEMBL3543083 0.80 ACHE (0.36) ABCB1ALDH1A1ABCG2ACHE
SCHEMBL5094562 0.80 CYP26A1 (0.37) LMNAALDH1A1NPSR1PARP1
SCHEMBL2794818 0.73 LDHA (0.35) LMNAPKMALDH1A1NPSR1
SCHEMBL3778768 0.73 LDHA (0.35) LMNAPKMALDH1A1NPSR1
SCHEMBL2795206 0.73 KMT2A (0.37) LMNAALDH1A1NPSR1
SCHEMBL3631986 0.73 KMT2A (0.37) LMNAALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718672-B2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2010-05-18 US disclosed
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy MILLER DUANE D 2008-02-07 US disclosed
US-20070270460-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE MILLER DUANE D 2007-11-22 US disclosed
US-7241774-B2 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2007-07-10 US disclosed
EP-1483233-A4 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE UNIV TENNESSEE RES CORP (US) 2005-12-21 EP disclosed
EP-1483233-A2 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE The University of Tennessee Research Corporation (US) 2004-12-08 EP disclosed
US-20040019078-A1 Substituted tetrahydroisoquinoline compounds, methods of making, and their use UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION,THE 2004-01-29 US disclosed
WO-2003077874-A2 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033007-A1 Substituted Tetrahydroisoquinoline Compounds for Cancer Therapy BAD, TP53, MCL1 ABCB1 556/4885ABCC1 1702/4885LMNA 3334/4885
US-20070270460-A1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, METHODS OF MAKING, AND THEIR USE BAX, CASP3, BAD ABCB1 67/4885ABCC1 1240/4885LMNA 877/4885
US-20040019078-A1 Substituted tetrahydroisoquinoline compounds, methods of making, and their use BAD, BAX, CASP3 ABCB1 61/4885ABCC1 1417/4885LMNA 857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.